|
BRPI0307077A2
(pt)
*
|
2002-01-22 |
2017-06-20 |
Biomatera Inc |
método para secar polímeros biodegradáveis
|
|
RS54876B1
(sr)
|
2005-05-10 |
2016-10-31 |
Incyte Holdings Corp |
Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
|
|
ES2540561T3
(es)
|
2005-12-20 |
2015-07-10 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
|
|
WO2008036642A2
(en)
|
2006-09-19 |
2008-03-27 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
DK2315756T5
(en)
|
2008-07-08 |
2015-08-03 |
Incyte Corp |
1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase
|
|
CN102558083B
(zh)
*
|
2010-12-22 |
2015-07-01 |
无锡药明康德生物技术有限公司 |
N,n-双取代-3-氨基异噁唑-5-甲醇化合物的合成方法
|
|
CN102558084A
(zh)
*
|
2010-12-22 |
2012-07-11 |
上海药明康德新药开发有限公司 |
N,n-双取代-3-氨基异噁唑-5-羧酸化合物的合成方法
|
|
GB201120860D0
(en)
|
2011-12-05 |
2012-01-18 |
Cambridge Entpr Ltd |
Cancer immunotherapy
|
|
HK1209742A1
(en)
|
2012-11-20 |
2016-04-08 |
沃泰克斯药物股份有限公司 |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
|
|
TWI651311B
(zh)
|
2013-11-08 |
2019-02-21 |
英塞特控股公司 |
用於合成吲哚胺２，３－雙加氧酶抑制劑之方法
|
|
LT3087071T
(lt)
|
2013-12-24 |
2018-11-12 |
Bristol-Myers Squibb Company |
Tricikliniai junginiai kaip priešvėžiniai agentai
|
|
RS59643B1
(sr)
|
2014-06-06 |
2020-01-31 |
Bristol Myers Squibb Co |
Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
|
|
RU2016149812A
(ru)
*
|
2014-06-06 |
2018-07-17 |
Флексус Байосайенсиз, Инк. |
Иммунорегулирующие средства
|
|
WO2016081748A2
(en)
|
2014-11-21 |
2016-05-26 |
Bristol-Myers Squibb Company |
Antibodies against cd73 and uses thereof
|
|
US10525035B2
(en)
|
2014-12-18 |
2020-01-07 |
Lankenau Institute For Medical Research |
Methods and compositions for the treatment of retinopathy and other ocular diseases
|
|
TW201630907A
(zh)
|
2014-12-22 |
2016-09-01 |
必治妥美雅史谷比公司 |
ＴＧＦβＲ拮抗劑
|
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
|
WO2016140884A1
(en)
|
2015-03-02 |
2016-09-09 |
Rigel Pharmaceuticals, Inc. |
TGF-β INHIBITORS
|
|
US10399933B2
(en)
|
2015-04-03 |
2019-09-03 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
|
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
Ｆ 星生物科技有限公司 |
Ｈｅｒ２結合劑治療
|
|
CN107709365A
(zh)
|
2015-04-13 |
2018-02-16 |
戊瑞治疗有限公司 |
癌症组合疗法
|
|
US10683290B2
(en)
|
2015-05-11 |
2020-06-16 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
EP3307740B1
(en)
|
2015-05-12 |
2019-12-18 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
PT3303396T
(pt)
|
2015-05-29 |
2023-01-30 |
Bristol Myers Squibb Co |
Anticorpos contra ox40 e utilizações dos mesmos
|
|
UY36757A
(es)
|
2015-06-29 |
2016-12-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
|
|
EP3328861A1
(en)
|
2015-07-28 |
2018-06-06 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
WO2017035118A1
(en)
|
2015-08-25 |
2017-03-02 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
MX2018005517A
(es)
|
2015-11-02 |
2018-11-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
|
|
EA201891121A1
(ru)
|
2015-11-19 |
2018-12-28 |
Бристол-Майерс Сквибб Компани |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
|
|
TWI791422B
(zh)
|
2015-11-23 |
2023-02-11 |
美商戊瑞治療有限公司 |
用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
|
|
EP3390406A1
(en)
|
2015-12-15 |
2018-10-24 |
Bristol-Myers Squibb Company |
Cxcr4 receptor antagonists
|
|
EP3416725A1
(en)
|
2016-02-19 |
2018-12-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of obesity
|
|
RU2638530C2
(ru)
*
|
2016-02-29 |
2017-12-14 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) |
ПРОИЗВОДНЫЕ 5-АМИНОИЗОКСАЗОЛА - КОНФОРМАЦИОННО-ЖЕСТКИЕ АНАЛОГИ γ-АМИНОМАСЛЯНОЙ КИСЛОТЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
|
|
SG11201806861SA
(en)
|
2016-03-04 |
2018-09-27 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
|
WO2017184619A2
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
US10696648B2
(en)
|
2016-05-04 |
2020-06-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN109414421A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
JP2019519485A
(ja)
|
2016-05-04 |
2019-07-11 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
|
|
KR20190004742A
(ko)
|
2016-05-04 |
2019-01-14 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
|
US10323004B2
(en)
|
2016-05-04 |
2019-06-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2018013818A2
(en)
|
2016-07-14 |
2018-01-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
US20190292179A1
(en)
|
2016-07-21 |
2019-09-26 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
WO2018039518A1
(en)
|
2016-08-26 |
2018-03-01 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
UY37466A
(es)
|
2016-11-03 |
2018-01-31 |
Phenex Discovery Verwaltungs Gmbh |
N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
|
|
HUE054272T2
(hu)
|
2016-12-22 |
2021-09-28 |
Calithera Biosciences Inc |
Összetételek és módszerek az argináz-tevékenység gátlásához
|
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
WO2018136437A2
(en)
|
2017-01-17 |
2018-07-26 |
Tesaro, Inc. |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
|
CA3057312A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Merck Sharp & Dohme Corp. |
Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
EP3601353A1
(en)
|
2017-03-31 |
2020-02-05 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
EP3612030B1
(en)
|
2017-04-21 |
2025-12-24 |
Ikena Oncology, Inc. |
Indole ahr inhibitors and uses thereof
|
|
MX2019012849A
(es)
|
2017-04-28 |
2019-11-28 |
Five Prime Therapeutics Inc |
Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
|
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
RU2658837C1
(ru)
*
|
2017-06-30 |
2018-06-25 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) |
Способ получения 5-аминоизоксазолкарбоновой кислоты
|
|
CN111093651B
(zh)
|
2017-06-30 |
2023-06-06 |
百时美施贵宝公司 |
Ido抑制剂的无定形和结晶形式
|
|
JP7186764B2
(ja)
|
2017-07-28 |
2022-12-09 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
|
EP3668496A4
(en)
|
2017-08-17 |
2021-07-14 |
Ikena Oncology, Inc. |
AHR INHIBITORS AND THEIR USES
|
|
JP7209697B2
(ja)
|
2017-08-31 |
2023-01-20 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
|
ES2904317T3
(es)
|
2017-08-31 |
2022-04-04 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticancerosos
|
|
CN111032672B
(zh)
|
2017-08-31 |
2024-09-13 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
|
US20200261414A1
(en)
|
2017-09-14 |
2020-08-20 |
Lankenau Institute For Medical Research |
Methods and compositions for the treatment of cancer
|
|
WO2019074822A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
WO2019074824A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
EP3694867B1
(en)
|
2017-10-10 |
2025-12-24 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
|
US11427610B2
(en)
|
2017-10-16 |
2022-08-30 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
|
WO2019090198A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
EP3724177A1
(en)
|
2017-12-12 |
2020-10-21 |
Phenex Discovery Verwaltungs-GmbH |
Oxalamides as modulators of indoleamine 2,3-dioxygenase
|
|
JP7284759B2
(ja)
|
2017-12-27 |
2023-05-31 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｃｄ４０抗体およびその使用
|
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｉｍ３に対する抗体およびその使用
|
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
KR20200130362A
(ko)
|
2018-03-08 |
2020-11-18 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
WO2019183040A1
(en)
|
2018-03-21 |
2019-09-26 |
Five Prime Therapeutics, Inc. |
ANTIBODIES BINDING TO VISTA AT ACIDIC pH
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
WO2019185870A1
(en)
|
2018-03-29 |
2019-10-03 |
Phenex Discovery Verwaltungs-GmbH |
Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
|
|
EP3773714A1
(en)
|
2018-04-12 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
AU2019255196A1
(en)
|
2018-04-16 |
2020-11-12 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
|
WO2019206800A1
(en)
|
2018-04-24 |
2019-10-31 |
Phenex Discovery Verwaltungs-GmbH |
Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
|
|
WO2019213340A1
(en)
|
2018-05-03 |
2019-11-07 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
|
FI3814348T3
(fi)
|
2018-06-27 |
2023-09-22 |
Bristol Myers Squibb Co |
Substituoituja naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina
|
|
LT3814347T
(lt)
|
2018-06-27 |
2023-07-10 |
Bristol-Myers Squibb Company |
Naftiridinono junginiai naudotini kaip t ląstelių aktyvatoriai
|
|
PE20211604A1
(es)
|
2018-07-09 |
2021-08-23 |
Five Prime Therapeutics Inc |
Anticuerpos de union a ilt4
|
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
|
EP3823604A4
(en)
|
2018-07-17 |
2022-03-16 |
Board of Regents, The University of Texas System |
COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE
|
|
WO2020023355A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US12145927B2
(en)
|
2018-07-23 |
2024-11-19 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
|
US12152019B2
(en)
|
2018-10-17 |
2024-11-26 |
Merck Sharp & Dohme Llc |
Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
WO2020102501A1
(en)
|
2018-11-16 |
2020-05-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a antibodies and uses thereof
|
|
US12012374B2
(en)
|
2019-05-13 |
2024-06-18 |
Bristol-Myers Squibb Company |
Agonists of ROR GAMMAt
|
|
US20230295087A1
(en)
|
2019-05-13 |
2023-09-21 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
CN111943906B
(zh)
*
|
2019-05-14 |
2023-12-15 |
中国医学科学院药物研究所 |
脒类衍生物、及其制法和药物组合物与用途
|
|
WO2021026179A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
MX2022003204A
(es)
|
2019-09-19 |
2022-04-18 |
Bristol Myers Squibb Co |
Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido.
|
|
US11548870B2
(en)
|
2019-11-19 |
2023-01-10 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of helios protein
|
|
US12527783B2
(en)
|
2019-11-26 |
2026-01-20 |
Bristol-Myers Squibb Company |
Salts/cocrystals of (R)-N-(4-chlorophenyl-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
|
CA3159317A1
(en)
|
2019-11-26 |
2021-06-03 |
Alfredo C. Castro |
Polymorphic carbazole derivatives and uses thereof
|
|
WO2021133748A1
(en)
|
2019-12-23 |
2021-07-01 |
Bristol-Myers Squibb Company |
Substituted quinolinonyl piperazine compounds useful as t cell activators
|
|
AU2020412698A1
(en)
|
2019-12-23 |
2022-08-18 |
Bristol-Myers Squibb Company |
Substituted piperazine derivatives useful as T cell activators
|
|
EP4081516B1
(en)
|
2019-12-23 |
2025-07-30 |
Bristol-Myers Squibb Company |
Substituted quinazolinyl compounds useful as t cell activators
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
CN114846015B
(zh)
|
2019-12-23 |
2024-07-30 |
百时美施贵宝公司 |
用作t细胞激活剂的经取代的杂芳基化合物
|
|
US20230045791A1
(en)
|
2020-01-06 |
2023-02-16 |
Hifibio (Hk) Limited |
Anti-tnfr2 antibody and uses thereof
|
|
AU2021205143A1
(en)
|
2020-01-07 |
2022-07-28 |
Hifibio, Inc. |
Anti-Galectin-9 antibody and uses thereof
|
|
US11534441B2
(en)
|
2020-01-15 |
2022-12-27 |
Blueprint Medicines Corporation |
MAP4K1 inhibitors
|
|
KR20220151189A
(ko)
|
2020-03-09 |
2022-11-14 |
브리스톨-마이어스 스큅 컴퍼니 |
증진된 효능제 활성을 갖는 cd40에 대한 항체
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
CA3188996A1
(en)
|
2020-08-10 |
2022-02-17 |
Tengfei XIAO |
Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
|
|
CN112521357B
(zh)
*
|
2020-08-31 |
2021-10-08 |
深圳瑞健生物科技有限公司 |
一种长效低成瘾性hnk衍生物及其制备方法
|
|
US20230416382A1
(en)
|
2020-10-14 |
2023-12-28 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
CA3202330A1
(en)
|
2020-12-16 |
2022-06-23 |
Anthony Casarez |
Compounds useful as t cell activators
|
|
US20240109899A1
(en)
|
2021-02-04 |
2024-04-04 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
|
EP4291558A1
(en)
|
2021-02-12 |
2023-12-20 |
F. Hoffmann-La Roche AG |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
EP4305041A1
(en)
|
2021-03-08 |
2024-01-17 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
JP2024515545A
(ja)
|
2021-04-05 |
2024-04-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
がん治療のためのピリジニル置換オキソイソインドリン化合物
|
|
PE20231941A1
(es)
|
2021-04-06 |
2023-12-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
|
TW202321237A
(zh)
|
2021-07-14 |
2023-06-01 |
美商纜圖藥品公司 |
Ｍａｐ４ｋ１抑制劑
|
|
WO2023288264A1
(en)
|
2021-07-15 |
2023-01-19 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
EP4472963A1
(en)
|
2022-02-01 |
2024-12-11 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
CN119654312A
(zh)
|
2022-08-08 |
2025-03-18 |
百时美施贵宝公司 |
用作t细胞活化剂的取代的四唑基化合物
|
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
|
TW202417001A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫吖呯衍生物
|
|
EP4568958A1
(en)
|
2022-08-11 |
2025-06-18 |
F. Hoffmann-La Roche AG |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
TW202417439A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫噻吖呯衍生物
|
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
GB202303250D0
(en)
|
2023-03-06 |
2023-04-19 |
King S College London |
Method and compounds
|
|
TW202500139A
(zh)
|
2023-05-08 |
2025-01-01 |
美商必治妥美雅史谷比公司 |
經取代之苯基㗁唑酮化合物
|
|
TW202509014A
(zh)
|
2023-05-10 |
2025-03-01 |
美商纜圖藥品公司 |
ＧＳＫ３α抑制劑及其使用方法
|
|
WO2024249540A1
(en)
|
2023-05-31 |
2024-12-05 |
Bristol-Myers Squibb Company |
Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
|
|
AU2024285766A1
(en)
|
2023-06-07 |
2026-01-08 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
|
WO2024263853A1
(en)
|
2023-06-23 |
2024-12-26 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
WO2025064197A1
(en)
|
2023-09-02 |
2025-03-27 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
|
AR133696A1
(es)
|
2023-09-02 |
2025-10-22 |
Bristol Myers Squibb Co |
Compuestos de fenil oxooxazolil piperidinadiona sustituida
|
|
JP7808733B2
(ja)
|
2023-09-13 |
2026-01-29 |
ブリストル－マイヤーズ スクイブ カンパニー |
置換オキソイソインドリニルピペリジン－２，６－ジオン化合物
|
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
US20250145590A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025226767A1
(en)
|
2024-04-24 |
2025-10-30 |
Bristol-Myers Squibb Company |
Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
|